Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransCode Therapeutics ( (RNAZ) ) has issued an update.
On October 14, 2025, TransCode Therapeutics announced the completion of its Phase 1a clinical trial for TTX-MC138, an investigational inhibitor of microRNA-10b, showing promising safety and efficacy results. The trial met its primary safety endpoint and defined a recommended Phase 2 dose, with 44% of patients experiencing stable disease for over four months, supporting advancement to a Phase 2a trial. The results suggest TTX-MC138’s potential as a new therapeutic option for metastatic diseases, aligning with its mechanism of action and offering a basis for further efficacy evaluation.
The most recent analyst rating on (RNAZ) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics is an immuno-oncology and targeted cancer therapy company focused on treating advanced malignancy. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis. TransCode also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to combat cancer cells.
Average Trading Volume: 210,972
Technical Sentiment Signal: Sell
Current Market Cap: $11.8M
See more insights into RNAZ stock on TipRanks’ Stock Analysis page.